A Phase 2 interventional study of pemetrexed in Non-small Cell Lung Cancer, Mesothelioma and Lung Neoplasms, sponsored by Eli Lilly and Company. Completed at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-07-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 157th largest by enrollment of the 224 interventional ones that give a count, is one of 25 that started in 2006, is one of 128 in phase 2, and was the 33rd registered.
7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 48 · Phase 4 8
First in 2001; this study’s year is marked. 25 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 224 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 228 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 122nd largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2006, is one of 73 in phase 2, and was the 37th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
This study will test the effects of pemetrexed on mesothelioma and non-small cell lung cancer patients with fluid around their lungs or abdomen.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed 500 mg/m\^2 intravenous (IV) every 21 days for 6 cycles
Drug: pemetrexed
500 milligrams per meter squared (mg/m\^2) IV every 21 days for 6 cycles
Also known as: LY231514, Alimta
Overview of Adverse Events
Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Time frame: baseline, up to 18 weeks
Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities
Number of participants with laboratory and non-laboratory toxicities possibly related to study drug, which were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. Grades range from 0 (none) to 5 (death). Grade 3 is severe and Grade 4 is life-threatening. NOS = Not otherwise specified.
Time frame: baseline, up to 18 weeks
Pemetrexed Population Pharmacokinetics (PK): Clearance
Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.
Time frame: Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion
Pemetrexed Population Pharmacokinetics: Volume of Distribution
Volume of distribution is the theoretical size of the compartment necessary to account for total drug amount in the body if it were present throughout the body in the same concentration found in plasma. Volume of distribution is defined as distribution of pemetrexed in the body and is determined by volume of distribution = dose/drug concentration. By knowing dose and measuring concentration of pemetrexed in plasma, volume was calculated. Central volume (V1) was determined by dose/peak serum level of pemetrexed. Peripheral volume (V2) is sum of all tissue spaces outside the central compartment.
Time frame: Cycle 1 and Cycle 2: before the end of infusion (approximately 9.5 minutes), 2 hours, 9-10 hours, 24-48 hours, 480-528 hours (20 to 22 days) after start of pemetrexed infusion
Discontinuations Due to Adverse Events
Adverse events were coded using the Medical Dictionary for Regulatory Activities, Version 11.0.
Time frame: baseline, up to 18 weeks
Overall Tumor Response
Overall tumor response was determined using Response Evaluation Criteria In Solid Tumors (RECIST), which defines when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions. PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions. PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions. SD (stable disease) = small changes that do not meet above criteria.
Time frame: baseline, up to 18 weeks
| Milestone | Pemetrexed |
|---|---|
| Started | 31 |
| Completed | 6 |
| Not completed | 25 |
| Withdrew: Adverse event | 2 |
| Withdrew: Physician decision | 3 |
| Withdrew: Progressive disease | 15 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Death | 2 |
Number of participants with laboratory and non-laboratory toxicities possibly related to study drug, which were graded using the Common Terminology Criteria for Adverse Events version 3.0 (CTCAE v3.0) for defining and grading specific adverse events. Grades range from 0 (none) to 5 (death). Grade 3 is severe and Grade 4 is life-threatening. NOS = Not otherwise specified.
| participants | Pemetrexed |
|---|---|
| Leukocytopenia | 1 |
| Neutropenia/Granulocytopenia | 1 |
| Platelets | 1 |
| Ascites (Non-Malignant) | 1 |
| Febrile Neutropenia | 1 |
| Pain Pulmonary/Upper Respiratory-Chest/Thorax NOS | 1 |
| Pleural Effusion (Non-Malignant) | 1 |
Clearance (CL) can be defined as the volume of plasma which is completely cleared of drug (pemetrexed) per unit time. Total body clearance is calculated after intravenous administration of the drug (pemetrexed) and is measured by taking plasma samples at various timepoints and measuring the amount of pemetrexed in the plasma.
| milliliter per minute (mL/min) | Pemetrexed |
|---|---|
| Pemetrexed Population Pharmacokinetics (PK): Clearance | 85.6 ± 21.4 |
Volume of distribution is the theoretical size of the compartment necessary to account for total drug amount in the body if it were present throughout the body in the same concentration found in plasma. Volume of distribution is defined as distribution of pemetrexed in the body and is determined by volume of distribution = dose/drug concentration. By knowing dose and measuring concentration of pemetrexed in plasma, volume was calculated. Central volume (V1) was determined by dose/peak serum level of pemetrexed. Peripheral volume (V2) is sum of all tissue spaces outside the central compartment.
| Liters (L) | Pemetrexed |
|---|---|
| Central Volume of Distribution | 6.61 ± 1.32 |
| Peripheral Volume of Distribution (V2) | 8.91 ± 1.68 |
| Peripheral Volume of Distribution (V3) | 1.26 ± 0 |
Overall tumor response was determined using Response Evaluation Criteria In Solid Tumors (RECIST), which defines when cancer patients improve ("respond"), stay the same ("stabilize"), or worsen ("progression") during treatments. CR (complete response) = disappearance of all target lesions. PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions. PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions. SD (stable disease) = small changes that do not meet above criteria.
| participants | Pemetrexed |
|---|---|
| Complete Response | 0 |
| Partial Response | 2 |
| Stable Disease | 8 |
| Progressive Disease | 12 |
| Unknown | 9 |
Adverse events were coded using the Medical Dictionary for Regulatory Activities, Version 11.0.
| participants | Pemetrexed |
|---|---|
| Atrial fibrillation | 1 |
| Febrile neutropenia (possibly related) | 1 |
| Pneumonia (resulted in death) | 1 |
| Respiratory failure (resulted in death) | 1 |
Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
| participants | Pemetrexed |
|---|---|
| TEAE - All, regardless of causality | 28 |
| TEAE - Possibly related to study drug | 23 |
| SAE - All, regardless of causality | 12 |
| SAE - Possibly related to study drug | 1 |
| Discontinuations Due to SAEs (including death) | 4 |
| Discontinuations - Possibly related to study drug | 1 |
| Discontinuations Due to Nonserious AEs | 0 |
| Deaths - On Study | 2 |
| Deaths - Possibly related to study drug | 0 |
| Deaths - Within 30 days of Study Discontinuation | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed | — | 12/31 (38.7%) | 28/31 (90.3%) |
| Event | Pemetrexed |
|---|---|
| Atrial fibrillationCardiac disorders | 3/31 |
| Abdominal painGastrointestinal disorders | 2/31 |
| PyrexiaGeneral disorders | 2/31 |
| PneumoniaInfections and infestations | 2/31 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 2/31 |
| AnaemiaBlood and lymphatic system disorders | 1/31 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/31 |
| ThrombocytopeniaBlood and lymphatic system disorders | 1/31 |
| Cardiac failureCardiac disorders | 1/31 |
| Pericardial effusionCardiac disorders | 1/31 |
| Event | Pemetrexed |
|---|---|
| NauseaGastrointestinal disorders | 10/31 |
| FatigueGeneral disorders | 9/31 |
| AstheniaGeneral disorders | 8/31 |
| ConstipationGastrointestinal disorders | 7/31 |
| AnorexiaMetabolism and nutrition disorders | 7/31 |
| AnaemiaBlood and lymphatic system disorders | 5/31 |
| Oedema peripheralGeneral disorders | 5/31 |
| DizzinessNervous system disorders | 5/31 |
| CoughRespiratory, thoracic and mediastinal disorders | 5/31 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/31 |
| Age Continuous(years) | Pemetrexed |
|---|---|
| Median | 62.7 (35.7 to 77.5) |
| Sex: Female, Male(Participants) | Pemetrexed |
|---|---|
| Female | 4 |
| Male | 27 |
| Race/Ethnicity, Customized(participants) | Pemetrexed |
|---|---|
| Caucasian | 30 |
| Hispanic | 1 |
| Region of Enrollment(participants) | Pemetrexed |
|---|---|
| Spain | 12 |
| Denmark | 6 |
| Germany | 13 |
| Diagnosis(participants) | Pemetrexed |
|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | 23 |
| Mesothelioma | 8 |
| Disease Stage(participants) | Pemetrexed |
|---|---|
| Stage III (locally advanced disease) | 12 |
| Stage IV (metastatic disease) | 18 |
| Unknown | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(participants) | Pemetrexed |
|---|---|
| 0 - Fully Active | 14 |
| 1 - Ambulatory, Restricted Strenuous Activity | 17 |
| Fluid Severity(participants) | Pemetrexed |
|---|---|
| Mild | 15 |
| Moderate | 14 |
| Severe | 2 |
5 further baseline measures are reported on the registry.
The record gives a start of Dec 2006, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pemetrexed
Carcinoma, Non-Small-Cell Lung →